Eli Lilly and Incyte's JAK inhibitor Olumiant reduced the risk of death by 13% in hospitalised COVID-19 patients when added to other drugs, according to new results from the UK RECOVERY trial.

Olumiant is approved to treat moderately to severely active rheumatoid arthritis (RA) in around 50 markets, but its competitiveness has been held back somewhat in the US by the FDA’s decision ...